NNNN · Nasdaq · ·
US$6.16+2.2%9월 29일 종가
기업이 직접 제출한 6-K에서 가져왔습니다.
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of IVD products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and six key platforms for biomarker detection. These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a strong global presence across the EU, APAC, and the Americas, the Company’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.
발표 자료 말미에 실린 기업 자신의 소개글입니다.
인용문과 회사 설명은 Anbio Biotechnology이(가) 2025년 12월 30일에 실적과 함께 제출한 6-K에서 가져왔으며, 표는 분기 보고서를 바탕으로 작성했습니다. EDGAR에서 발표 자료 보기 주가는 액면분할과 배당을 반영해 조정했습니다.
Anbio Biotechnology의 실적 발표 콜 녹취록이 없습니다.